ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 101 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2014. The put-call ratio across all filers is 1.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $3,053,000 | -18.1% | 57,314 | -4.5% | 0.01% | -20.0% |
| Q2 2017 | $3,728,000 | +13.8% | 60,023 | +24.2% | 0.02% | +15.4% |
| Q1 2017 | $3,276,000 | -5.6% | 48,338 | -2.1% | 0.01% | -7.1% |
| Q4 2016 | $3,472,000 | -0.5% | 49,387 | +0.4% | 0.01% | -6.7% |
| Q3 2016 | $3,490,000 | -8.1% | 49,200 | -36.6% | 0.02% | -6.2% |
| Q2 2016 | $3,796,000 | -31.7% | 77,610 | -11.2% | 0.02% | -33.3% |
| Q1 2016 | $5,555,000 | -39.1% | 87,371 | +7.5% | 0.02% | -38.5% |
| Q4 2015 | $9,121,000 | +13.5% | 81,305 | -2.5% | 0.04% | +8.3% |
| Q3 2015 | $8,033,000 | +5.9% | 83,410 | +12.5% | 0.04% | +16.1% |
| Q2 2015 | $7,589,000 | +110.6% | 74,119 | +27.7% | 0.03% | +106.7% |
| Q1 2015 | $3,604,000 | +55.9% | 58,050 | +10.2% | 0.02% | +50.0% |
| Q4 2014 | $2,312,000 | -12.3% | 52,699 | +13.2% | 0.01% | -9.1% |
| Q3 2014 | $2,635,000 | +234.4% | 46,547 | +165.1% | 0.01% | +266.7% |
| Q2 2014 | $788,000 | +59.2% | 17,555 | +73.2% | 0.00% | +50.0% |
| Q1 2014 | $495,000 | – | 10,133 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |